Volker Schellenberger
About Volker Schellenberger
Volker Schellenberger is the Chief Technology Officer and co-founder of Amunix, with extensive experience in protein engineering and drug discovery.
Volker Schellenberger's Professional Title and Role
Volker Schellenberger serves as the Chief Technology Officer and is the co-founder of Amunix. His role involves overseeing technological advancements and guiding strategic initiatives in developing innovative solutions in the field of protein engineering and drug discovery.
Educational Background of Volker Schellenberger
Volker Schellenberger earned his Ph.D. from Leipzig University, where he specialized in protease-catalyzed peptide synthesis. Following his Ph.D., he conducted postdoctoral studies at the Institute for Protein Research in Pushchino, Russia, and the University of Göttingen, where he developed a novel method for peptide production from recombinant peptide-multimers. Additionally, Schellenberger completed a postdoctoral fellowship with Bill Rutter at the University of California, San Francisco.
Volker Schellenberger's Industry Experience and Innovations
Volker Schellenberger has extensive experience in the field of protein engineering and drug discovery. He previously led the Protein Engineering department at Genencor. During his career, he invented several key technologies including combinatorial consensus mutagenesis, selection by micro-compartmentalization, and mutator technology. His innovations have significantly contributed to advancements in enzyme optimization for industrial applications and metabolic pathway engineering in microbes.
Collaborations Initiated by Volker Schellenberger
During his tenure, Volker Schellenberger initiated and led collaborative projects with Seattle Genetics, focusing on the development of antibody-enzyme fusion proteins. These collaborations have been instrumental in advancing research and development in the biotechnology and pharmaceutical sectors.
Publications and Patents by Volker Schellenberger
Volker Schellenberger is the author of over 40 scientific papers and holds more than 70 issued and pending patent applications. His prolific output reflects his significant contributions to the fields of protein engineering and biotechnology.